Blincyto Injection (35mcg), also known by its generic name Blinatumomab, is a targeted immunotherapy medication primarily used in the treatment of certain types of blood cancers, specifically acute lymphoblastic leukemia (ALL). This drug is designed to engage the body’s immune system to fight cancer cells by linking T-cells, a type of white blood cell, to the cancer cells, thereby facilitating their destruction. Blincyto is composed of a bispecific T-cell engager (BiTE) antibody that specifically binds to CD19, a protein found on the surface of B-cell malignancies, and CD3, a component of the T-cell receptor complex. This unique mechanism allows for a more precise attack on cancer cells while sparing normal cells, which is a significant advancement in cancer therapy. Blincyto is administered via continuous intravenous infusion, and its formulation is designed to ensure stability and efficacy during treatment. As a result, it represents a promising option for patients with relapsed or refractory ALL, offering hope for improved outcomes in a challenging disease landscape.